XML 32 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2012
Mar. 31, 2016
USD ($)
Tranche
Segment
shares
Mar. 31, 2015
USD ($)
shares
Dec. 31, 2015
USD ($)
shares
Nov. 30, 2015
USD ($)
Mar. 05, 2015
USD ($)
Dec. 31, 2014
shares
May. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Dec. 06, 2012
USD ($)
Significant Accounting Policies [Line Items]                    
Sales discount percentage   2.00%                
Sales discount term   30 days                
Trade receivables, credit period   30 days                
Number of tranches for private placement transaction | Tranche   2                
Accounts receivable written off   $ 0                
Other long-term assets   $ 174,000   $ 174,000            
Warrants outstanding | shares   0                
Gain (loss) on change in fair value of derivative liability   $ (1,250,000) $ 464,000              
Number of operating segments | Segment   1                
BioPharma Debt                    
Significant Accounting Policies [Line Items]                    
Maximum repayment of future revenue and receivables   $ 134,600,000               $ 150,000,000
Fair value of embedded derivative liability                   $ 14,600,000
Gain (loss) on change in fair value of derivative liability   (400,000) 0              
Preferred Stock Purchase Option                    
Significant Accounting Policies [Line Items]                    
Gain (loss) on change in fair value of derivative liability     (946,000)              
Derivative liability at fair value           $ 900,000        
Embedded Derivative Financial Instruments                    
Significant Accounting Policies [Line Items]                    
Gain (loss) on change in fair value of derivative liability   (1,250,000) $ 1,300,000              
Embedded Derivative Financial Instruments | BioPharma Debt                    
Significant Accounting Policies [Line Items]                    
Maximum repayment of future revenue and receivables                 $ 150,000,000  
Fair value of embedded derivative liability   5,900,000   5,500,000            
Gain (loss) on change in fair value of derivative liability   $ (400,000)                
Top Three Customers | Gross Product Sales | Customer Concentration Risk                    
Significant Accounting Policies [Line Items]                    
Concentration risk percentage   95.00% 94.00%              
Top Three Customers | Accounts Receivable | Customer Concentration Risk                    
Significant Accounting Policies [Line Items]                    
Concentration risk percentage   95.00% 94.00%              
Convertible Debt | 2014 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount               $ 27,900,000    
Fair value of embedded derivative liability   $ 2,800,000   2,100,000            
Gain (loss) on change in fair value of derivative liability   (700,000) $ 1,300,000 (700,000)            
Derivative liability at fair value               $ 3,500,000    
Convertible Debt | 2015 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount         $ 3,800,000          
Fair value of embedded derivative liability   700,000   600,000            
Gain (loss) on change in fair value of derivative liability   $ (100,000)   $ (100,000)            
Derivative liability at fair value         $ 500,000          
Convertible Debt | 2014 Notes and 2015 Notes                    
Significant Accounting Policies [Line Items]                    
Derivative liability fair value assumptions, dividend yield   27.70%   25.60%            
Derivative liability fair value assumptions, risk-free rate   2.40%   2.90%            
Derivative liability fair value assumptions, volatility rate   90.00%   89.00%            
Convertible Debt | 2012 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount   $ 0   $ 0            
Note, expected term 24 months                  
Non Cash | Convertible Debt | 2014 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount   22,500,000   24,100,000            
Non Cash | Convertible Debt | 2015 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount   $ 3,900,000   $ 4,200,000            
Warrants Issued October 2009                    
Significant Accounting Policies [Line Items]                    
Warrants outstanding | shares   0   0     8,087,388      
Warrants exercised | shares     1,844,585              
Warrants expired | shares     6,242,803              
Accounting Standards Update 2015-03 | Scenario, Adjustment                    
Significant Accounting Policies [Line Items]                    
Other long-term assets       $ (1,900,000)            
Unamortized debt issuance cost       $ 1,900,000            
Minimum | Embedded Derivative Financial Instruments | BioPharma Debt                    
Significant Accounting Policies [Line Items]                    
Derivative liability fair value assumptions, term   1 year 9 months 18 days   2 years            
Derivative liability fair value assumption, coupon rate   6.60%   6.60%            
Derivative liability fair value assumptions, market yields   12.30%   13.00%            
Maximum | Embedded Derivative Financial Instruments | BioPharma Debt                    
Significant Accounting Policies [Line Items]                    
Derivative liability fair value assumptions, term   7 years 1 month 6 days   7 years 3 months 18 days            
Derivative liability fair value assumption, coupon rate   12.50%   12.50%            
Derivative liability fair value assumptions, market yields   25.10%   30.70%